Herceptin ruling on hold

A decision on whether a potentially life-saving breast cancer drug will be funded by the Government will be known in two weeks.

Regulatory group Medsafe met yesterday to decide on the safety of the use of trastuzumab (Herceptin) for early HER2 positive breast cancer - an advanced and aggressive stage 2 breast cancer.